Cases reported "Acute-Phase Reaction"

Filter by keywords:



Filtering documents. Please wait...

1/1. Lepromatous leprosy and reversal reaction in a Micronesian immigrant.

    A 25-year-old Micronesian man from the island of Otia developed erythematous plaques on his legs. He was diagnosed with erythema nodosum and treated with systemic prednisone. Two months later, he presented with erythematous nodules on his forehead, cheeks, and chin (Fig. 1). Examination revealed scattered violaceous papules on his chest, arms, forearms, hands, and feet, and deep purple macules on his palms and soles. Laboratory evaluation included negative serologies for human immunodeficiency virus, rapid plasma reagin, and hepatitis a, B, and C. Routine histopathology revealed nodular aggregates of histiocytes, plasma cells, and lymphocytes. histiocytes showed basophilic clusters of organisms within vacuoles, suggesting globi. Acid-fast stain revealed numerous acid-fast-positive rod-shaped organisms. The bacterial index on the Fite stain was four (bacterial index/Ridley's logarithmic scale, indicating 10-100 bacteria/high power field) (Fig. 2). An acid-fast stain obtained from a smear of tissue was positive for acid-fast bacilli, but no acid-fast bacilli were cultured. After the first day of treatment with dapsone 100 mg, rifampin 600 mg, and clofazimine 50 mg, the patient complained of burning and pain in his ankles and wrists. There was intense erythema within the lesions. edema developed in his hands and feet. Consultation with the Gillis W. Long Hansen's disease Center in Carville, louisiana, recommended prompt treatment with corticosteroids. The edema of the hands and wrists was treated as a type I reversal reaction with prednisone 1 mg/kg/day. Subsequently, the edema and neuralgia quickly resolved in his distal extremities.
- - - - - - - - - -
ranking = 1
keywords = leprosy
(Clic here for more details about this article)


Leave a message about 'Acute-Phase Reaction'


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.